All News

Rituximab-pvvr (Ruxience, Pfizer) is approved to treat non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

Rituximab-pvvr (Ruxience, Pfizer) is approved for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.

A binational team of investigators at the University of California, Davis, has conducted the first comprehensive study to examine the risk factors for Rocky Mountain spotted fever in Mexicali, Mexico. They found that citywide, just 1 in 1000 ticks was infected with the disease, but in certain neighborhoods, about 1 in 10 ticks was infected.